Adlai Nortye Group Ltd. (ANL) fair value analysis
Nasdaq · Updated 2026-10-19
ANL price how computed
Valuation status
No fair-value estimate yetANL has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for ANL yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $11.03
- Sector
- Healthcare
- 12-month range
- $0.88–$16.60
- Market cap
- $648M
- From 52-week high
- -33.6%
- Shares outstanding
- 58.7M
- Rank in Healthcare by quality score
- #94 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Adlai Nortye Group Ltd. is a healthcare company listed on Nasdaq that provides medical services and solutions to patients across multiple regions. The company operates facilities and delivers healthcare services in various markets where it maintains a presence.
ANL currently ranks #94 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $648M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-0.82
- Gross margin
- 100.0%
- Debt / equity
- 0.12
- Revenue growth (3-yr avg)
- 64.5%
- Shares outstanding
- 58.7M
Derived indicators how computed
- Quality grade
- C
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 33 · neutral
- 50-day average
- $14.41
- 200-day average
- $10.94
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Last 8 quarters vs consensus
- 2 beat, 2 missed
- Quarter by quarter
- 2025-12 ▬ met
2025-09 ▬ met
2025-06 ▼ miss
2025-03 ▼ miss (-1.6%)
2024-09 ▲ beat (+100.0%)
2024-06 ▲ beat (+42.6%)
2023-12 ▬ met (0.0%)
2023-09 ▬ met (0.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 0 hold · 0 sell (7 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $29.5
- Target vs last price
- +167.5%
What our data shows for ANL
- Shares are trading in the middle of their 12-month price range of $0.88–$16.60.
- The 14-day relative strength index sits at a neutral 33.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ANL's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ANL conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for ANL showed a shift in momentum this week as the 50/200-day trend state transitioned from uptrend to mixed, suggesting a change in the stock's near-term directional bias. This development indicates that the healthcare sector stock is no longer demonstrating consistent bullish momentum across its key moving average crossovers. The current valuation verdict for ANL remains awaiting full valuation assessment.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ANL stock undervalued?
TickrTrends has no fair-value estimate for ANL yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is ANL's TickrTrends verdict?
ANL is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does ANL compare to other Healthcare stocks?
ANL ranks #94 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ANL overbought or oversold?
ANL's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does ANL usually beat earnings estimates?
Over its last 8 reported quarters ANL beat the consensus estimate 2 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ANL?
Of 7 analysts covering ANL, 7 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $29.5 (+167.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.